Interestingly, although EGFR is frequently activated in CRC and EGFR inhibitors are effective in a subset of CRCs (Sakata and Larson, 2022), the contribution of the NRG1 receptor complex ERBB2/3 signaling is more unclear. Here, ERBB2 is linked to colorectal carcinoma.